Skip to main content

Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer

Trial Status: Approved

This research study is studying at biomarkers in tissue samples from patients with stage I or stage III endometrial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

Inclusion Criteria

  • Histologically confirmed endometrioid endometrial cancer * Stage IA, IB, IC, or IIIC disease * Any grade
  • Enrolled and evaluated on GOG-0210 Molecular Staging Study of Endometrial Cancer * Consented to allow their specimens and clinical data to be collected and stored for future research
  • Underwent complete surgical staging, including the following: * Hysterectomy * Bilateral oophorectomy * Washings as well as pelvic lymphadenectomy (sampling of four left and four right pelvic lymph nodes) * Para-aortic lymphadenectomy (sampling of one left and one right para-aortic lymph node)
  • Sufficient high-quality frozen primary tumor for testing with ≥ 75% tumor cellularity and ≤ 10% necrosis

Pennsylvania

Philadelphia
Gynecologic Oncology Group
Status: CLOSED_TO_ACCRUAL_AND_INTERVENTION
Contact: David Scott Miller
Phone: 214-648-3026

PRIMARY OBJECTIVES:

I. To identify microRNA expression patterns associated with lymph node metastasis in samples from patients with endometrial cancer.

OUTLINE:

Banked tumor tissue specimens are analyzed for microRNA expression profiling by microarray analysis and reverse transcriptase-PCR assays.

Trial Phase Phase NA

Trial Type Ancillary-correlative

Lead Organization
Gynecologic Oncology Group

Principal Investigator
David Scott Miller

  • Primary ID GOG-8014
  • Secondary IDs NCI-2011-02231, CDR0000672415
  • Clinicaltrials.gov ID NCT01119573